GH|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $-0.30 | - | - |
| Q2'26 | $-0.42 | $-0.42 | -0.0% |
| Q1'26 | $-0.78 | $-0.45 | +42.1% |
| Q4'25 | $-0.72 | $-0.50 | +30.1% |
| Q3'25 | $-0.49 | $-0.39 | +20.3% |
| Q2'25 | $-0.51 | $-0.44 | +14.5% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $350M | - | - |
| Q2'26 | $324M | $335M | +3.5% |
| Q1'26 | $288M | $302M | +4.9% |
| Q4'25 | $279M | $281M | +0.9% |
| Q3'25 | - | $265M | - |
| Q2'25 | - | $232M | - |
Market Data
GH Stock Snapshot
GH is currently trading at $169.47, giving Guardant Health Inc a market cap of 22.66B. Today's range spans $158.00–$169.41, with shares opening at $161.76 and moving up $0.86 (0.5%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY) with a news sentiment reading of 47/100.
Over the past year GH has traded between $48.25 and $176.58 - the current price is +251.2% off the 52-week low and -4.0% from the high. 37 analysts cover the stock with a Buy consensus and a mean 12-month target of $194.29 (range $105.00–$225.00), implying upside of +14.6%.
In the Healthcare peer group, Guardant Health Inc (GH) stands out for a BUY signal backed by aligned sentiment - score 95/100, sentiment neutral at 47/100, price $169.47 (near 52-week highs). With 22.66B in market cap, this is large enough to feature on institutional watch lists but small enough to re-rate meaningfully on a positive earnings surprise. The 52-week span of $48.25–$176.58 shows the stock has already proven it can make significant moves.
Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (95/100) and news sentiment (47/100, neutral) supports the narrative, analyst upgrades follow price rather than lead it. At $169.47 (near 52-week highs), GH's position within the $48.25–$176.58 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Company Insights: Guardant Health Inc. (GH)
Guardant Health Inc. operates as a precision oncology company, focusing on advanced blood and tissue-based diagnostic tests to enhance cancer care. Its core Guardant360 platform offers comprehensive genomic profiling, including liquid biopsy, to guide treatment decisions across the cancer care continuum. The company's offerings span initial diagnosis, treatment monitoring, and recurrence detection, serving both clinical and biopharmaceutical customers.
The company's financial performance has shown a positive trajectory in recent quarters, with consistent revenue growth and an accelerating trend in earnings per share (EPS). Guardant Health has demonstrated a pattern of exceeding analyst EPS estimates for its last three reported quarters, signaling improving operational efficiency and market reception. This financial momentum is supported by strategic initiatives aimed at expanding its diagnostic capabilities.
Recent strategic moves, such as the acquisition of MetaSight Diagnostics and the expansion of its Shield colorectal cancer screening test, underscore Guardant Health's commitment to broadening its market reach. These initiatives are designed to bolster its multi-disease detection pipeline and explore new revenue streams in early cancer detection and other areas like liver fibrosis. Investors are closely monitoring the successful commercialization of these expanded platforms and their impact on future financial results.
Diagnostic Leadership
Guardant Health is a leader in precision oncology diagnostics, specializing in blood and tissue-based genomic profiling.
Its Guardant360 platform provides comprehensive insights for treatment decisions across the cancer care continuum.
The company serves both clinical oncologists and biopharmaceutical partners developing new therapies.
Financial Momentum
Recent quarters show consistent revenue growth, increasing from $201.8 million in Q4 2024 to $265.2 million in Q3 2025.
EPS performance has accelerated, with the company exceeding analyst estimates in its last three reported quarters.
This positive financial trend indicates strengthening market adoption and operational execution.
Strategic Expansion
The acquisition of MetaSight Diagnostics aims to enhance early cancer and liver fibrosis detection capabilities.
Expansion of the Shield colorectal cancer screening test through partnerships broadens market access.
These moves signal a focus on diversifying its diagnostic pipeline and capturing new market segments.
Market Position
Guardant Health operates in the high-growth diagnostics and research industry within healthcare.
Its focus on liquid biopsy and comprehensive genomic profiling addresses a critical need in oncology.
The company's market capitalization of over $11.5 billion reflects significant investor confidence in its growth potential.
Positioning GH
Guardant Health's stock performance is driven by its innovation in cancer diagnostics and its expanding commercial reach. Investors seeking exposure to precision oncology and diagnostic advancements may consider adding to positions on positive earnings surprises and successful integration of new technologies. Conversely, a reduction in exposure could be warranted if the company faces significant competitive pressures or delays in commercializing its expanded product pipeline.
GH Recent Earnings History
- Q4 2025
EPS: $-0.5 actual vs $-0.72 estimate (beat) · Revenue: $281M actual vs $279M estimate
- Q3 2025
EPS: $-0.39 actual vs $-0.49 estimate (beat) · Revenue: $265M actual
- Q2 2025
EPS: $-0.44 actual vs $-0.51 estimate (beat) · Revenue: $232M actual
- Q1 2025
EPS: $-0.49 actual vs $-0.59 estimate (beat) · Revenue: $203M actual
- Q4 2024
EPS: $-0.62 actual vs $-0.5 estimate (miss) · Revenue: $202M actual
Key Metrics for GH
Guardant Health's performance hinges on the adoption and reimbursement of its advanced cancer diagnostics. Investors should monitor key metrics reflecting test volume, revenue growth, and profitability.
Test Volume Growth: Measures the increase in the number of diagnostic tests performed by Guardant Health. Strong volume growth indicates increasing market penetration and physician adoption; declining volumes suggest competitive pressures or reimbursement challenges. This is crucial for GH as it directly drives revenue and supports future growth expectations.
Revenue Growth: Tracks the overall increase in sales for Guardant Health's diagnostic and research products. Accelerating revenue growth is positive, showing successful commercialization and market acceptance; slowing growth could signal market saturation or competitive headwinds. Sustained revenue expansion is vital for GH to achieve profitability and justify its valuation.
Gross Margin: Represents the profitability of Guardant Health's core testing services after accounting for direct costs. Expanding gross margins suggest operational efficiencies and pricing power; contracting margins may indicate rising costs or pricing pressures. Improving margins are essential for GH to reach sustainable profitability as test volumes scale.
Cash Flow from Operations: Indicates the cash generated from Guardant Health's primary business activities. Positive and growing operating cash flow is a sign of financial health and operational efficiency; negative or declining cash flow can signal cash burn. This metric is important for GH to fund its research, development, and commercial expansion without excessive reliance on external capital.
Reimbursement Rates: Reflects the percentage of claims for Guardant Health's tests that are approved and paid for by insurance providers. Higher and stable reimbursement rates are critical for revenue realization and market access; declining rates can severely impact GH's financial performance. Successful navigation of reimbursement landscapes is key to the long-term viability of Guardant Health's business model.
GH Competitive Positioning
Guardant Health Inc (GH) is tracked alongside these names in Diagnostics & Research on DailyIQ.
Analyst Price Targets for GH
The current spread of analyst price targets and ratings for Guardant Health Inc (GH).
Reflects the most recently tracked analyst ratings for GH and may lag real-time updates. Not a recommendation to buy or sell.
What Moves GH Stock?
Guardant Health's stock performance is primarily driven by the adoption of its advanced cancer detection tests and its ability to beat earnings expectations. The company's progress in expanding its screening platforms and strategic partnerships also significantly influences investor sentiment.
Test Adoption & Revenue
Guardant Health's core business relies on the increasing utilization of its Guardant360 and Shield tests for comprehensive genomic profiling and colorectal cancer screening. Strong commercial execution and expanding payer coverage are critical for driving higher test volumes and, consequently, revenue growth.
Higher test volumes translate directly into increased revenue, which is a key metric for investors. Consistent revenue growth, especially when exceeding analyst expectations, tends to boost the stock price by signaling market acceptance and future earnings potential.
Earnings Performance
The company's ability to meet or exceed earnings per share (EPS) estimates is a significant catalyst for its stock. Positive EPS surprises indicate efficient operations and strong demand for its diagnostic solutions, often leading to upward revisions in analyst forecasts.
Beating EPS expectations can lead to immediate stock price appreciation as investors react to the positive financial results. Conversely, missing estimates can trigger sell-offs, highlighting the sensitivity of the stock to profitability metrics.
Strategic Expansion
Guardant Health's strategic initiatives, such as the acquisition of MetaSight Diagnostics and the expansion of its Shield test through partnerships like the one with Quest Diagnostics, are designed to broaden its market reach and product pipeline. These moves aim to establish Guardant as a leader in multi-disease detection.
Successful integration of new technologies and the commercialization of expanded screening capabilities can unlock new revenue streams and enhance the company's long-term growth prospects. Positive developments in these areas are likely to be rewarded by investors with increased stock valuation.
Key insight: Guardant Health's stock is a play on the accelerating adoption of its innovative cancer diagnostics and its consistent ability to outperform on earnings. Investors should closely monitor test volume growth and the successful integration of its strategic expansion efforts.
Risk Factors
Guardant Health faces risks tied to the complex and evolving landscape of cancer diagnostics. Key concerns include the successful clinical validation and market adoption of its novel tests, as well as navigating reimbursement and regulatory hurdles.
- Clinical Validation
The efficacy and clinical utility of Guardant's diagnostic tests must be rigorously proven through extensive clinical trials. Failure to demonstrate superior performance or clear patient benefit could hinder adoption by physicians and payers. This risk materializes if trial results are inconclusive or negative, impacting future sales and partnerships.
- Reimbursement Risk
Securing favorable and broad reimbursement from government and private payers is critical for Guardant's revenue. Delays or denials in obtaining adequate coverage can significantly limit patient access and sales volume. This risk becomes a reality if payers deem the tests not cost-effective or medically necessary, impacting commercial viability.
- Regulatory Approval
Guardant's tests require stringent regulatory approvals, such as from the FDA, to be marketed and used clinically. Any setbacks or lengthy delays in the approval process can postpone market entry and revenue generation. This risk is present if the company faces unexpected challenges in meeting regulatory requirements or if new regulations emerge.
- Competition Risk
The precision oncology market is increasingly competitive, with both established players and emerging companies developing similar diagnostic technologies. Competitors may offer comparable or superior tests at lower costs, eroding Guardant's market share. This risk intensifies if competitors achieve faster regulatory approvals or secure key partnerships.
- Adoption Rate
Guardant's growth depends on the rapid adoption of its liquid biopsy and genomic profiling tests by oncologists and biopharmaceutical partners. Slow uptake due to physician inertia, integration challenges with existing workflows, or lack of awareness could impede revenue growth. This risk materializes if the company fails to effectively educate the market and demonstrate clear value propositions.
Frequently Asked Questions About GH
Is Guardant Health (GH) stock a good investment?
Guardant Health's investment case centers on its leadership in precision oncology diagnostics, particularly its liquid biopsy technology. The company's focus on improving cancer care through early detection and personalized treatment has significant market potential. Investors may consider the company's growth trajectory, competitive landscape, and the adoption rate of its diagnostic tests.
What drives Guardant Health (GH) stock price?
The stock price of Guardant Health is primarily influenced by the adoption and reimbursement of its advanced cancer diagnostic tests, such as Guardant360 and Shield. Key drivers include clinical trial results, regulatory approvals, strategic partnerships with healthcare providers and biopharmaceutical companies, and the company's ability to demonstrate improved patient outcomes and cost-effectiveness in cancer care.
Does Guardant Health (GH) pay a dividend?
Guardant Health currently does not pay a dividend to its shareholders. As a growth-oriented company in the biotechnology sector, it typically reinvests its earnings back into research and development, commercial expansion, and strategic acquisitions to fuel future growth.
What are the risks of investing in Guardant Health (GH)?
Investing in Guardant Health carries risks inherent to the healthcare and biotech sectors. These include intense competition from other diagnostic companies, challenges in obtaining favorable reimbursement from payors, the lengthy and complex regulatory approval process, and the potential for scientific or clinical setbacks. Execution risk related to commercialization and integration of new technologies also poses a threat.
How is Guardant Health (GH) performing financially?
Guardant Health has shown a positive trend in recent financial reports, with consistent revenue growth and an improving earnings per share (EPS) trend. The company has exceeded analyst EPS estimates in its last three reported quarters, indicating strong operational execution. Investors will be monitoring continued revenue acceleration and the impact of strategic initiatives on profitability.
What is Guardant Health's (GH) valuation outlook?
Guardant Health's valuation is largely dependent on its future revenue growth potential and market penetration in the precision oncology space. Analysts and investors often assess its market capitalization relative to its peers and its projected earnings capacity. Factors such as the expansion of its test portfolio and the success of its early cancer detection initiatives will be critical for its valuation.
What is Guardant Health's (GH) strategy for early cancer detection?
Guardant Health is actively expanding its focus on early cancer detection through initiatives like its Shield test for colorectal cancer and strategic acquisitions. The recent acquisition of MetaSight Diagnostics aims to bolster its multi-disease detection pipeline, signaling a commitment to broadening its clinical applications beyond advanced cancer diagnostics.
How does Guardant Health (GH) collaborate with biopharmaceutical companies?
Guardant Health partners with biopharmaceutical companies to support the development and commercialization of new cancer therapies. Its advanced genomic profiling tests provide crucial data for clinical trials, helping identify patient populations likely to respond to specific treatments and supporting companion diagnostic development.
What is the significance of Guardant Health's (GH) liquid biopsy technology?
The significance of Guardant Health's liquid biopsy technology lies in its ability to detect cancer through a simple blood draw, offering a less invasive alternative to traditional tissue biopsies. This technology enables comprehensive genomic profiling, which is crucial for guiding personalized treatment decisions and monitoring treatment response across various cancer types.
What are Guardant Health's (GH) growth catalysts?
Key growth catalysts for Guardant Health include the increasing adoption of its Shield test for colorectal cancer screening through partnerships like the one with Quest Diagnostics, successful integration of acquired technologies, and the expansion of its multi-cancer early detection capabilities. Continued positive clinical data and favorable reimbursement decisions will also be crucial.
Learn More
Advanced Chart Analysis: Scaling, Volume, and Comparative Charting Explained A comprehensive guide to advanced chart construction including arithmetic vs logarithmic scales, dual y-axes, multi-line comparisons, and volume-based charting techniques.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
The Basic Principle of Technical Analysis - The Trend Understand how trends form, why they matter, how they are identified, and the core assumptions technical analysts rely on when studying market price behavior.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.